GCMG:NASDAQGCM Grosvenor Inc. Analysis
Data as of 2026-06-14 - not real-time
$11.35
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
GCM Grosvenor (GCMG) is trading at $11.35, well below its DCF fair value of $21.02, implying roughly a 25% upside. The stock sits just above its 20‑day ($10.77) and 50‑day ($10.72) SMAs, and the MACD histogram is bullish (+0.084), while the RSI at 59 indicates room for further upside without being overbought. Volume is increasing and beta (≈0.98) suggests market‑level price movement, though 30‑day volatility is high at 37%, flagging short‑term price swings. The dividend yield of 4.23% is attractive, but the payout ratio is high at 92%; nevertheless, free cash flow ($115 M) comfortably exceeds the annual dividend payout, supporting sustainability. Recent material news includes an upcoming ex‑dividend date on June 5 and senior executives presenting at the Morgan Stanley and William Blair conferences, which should boost investor visibility and confidence.
Given the undervalued pricing, solid cash generation, and strong dividend, the stock presents a compelling case for accumulation. Sector‑level risk is moderate for asset management, and regulatory exposure is limited to standard financial oversight. The combination of technical bullishness, attractive valuation, and dividend appeal supports a buy stance across horizons.
Given the undervalued pricing, solid cash generation, and strong dividend, the stock presents a compelling case for accumulation. Sector‑level risk is moderate for asset management, and regulatory exposure is limited to standard financial oversight. The combination of technical bullishness, attractive valuation, and dividend appeal supports a buy stance across horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- High dividend yield with sustainable cash flow
- Increasing volume and upcoming ex‑dividend date
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation upside to DCF fair value
- Stable earnings growth (forward EPS $1.05) and improving margins
- Management visibility from conference presentations
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Undervalued relative to intrinsic value and industry peers
- Consistent dividend policy and strong free cash flow generation
- Diversified asset‑management platform with strategic growth focus
Key Metrics & Analysis
Financial Health
Revenue Growth-1.20%
Profit Margin9.11%
P/E Ratio22.7
ROE986.77%
ROA13.66%
Debt/Equity345.30
P/B Ratio26.5
Op. Cash Flow$202.0M
Free Cash Flow$115.4M
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI59.7
Support$9.84
Resistance$11.54
MA 20$10.77
MA 50$10.72
MA 200$11.29
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$21.02
Target Price$14.25
Upside/Downside25.55%
GradeUndervalued
TypeValue
Dividend Yield4.23%
Risk Assessment
Beta0.98
Volatility37.46%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.